How much profit has Hansa Biopharma made this year?
Hansa Biopharma has made -701.16 M SEK this year.
Hansa Biopharma Net Income 2024
Hansa Biopharma Net Income
-701.16 M SEK
Ticker
HNSA.ST
ISIN
SE0002148817
WKN
A0M65T
In 2024, Hansa Biopharma's profit amounted to -701.16 M SEK, a -15.7% increase from the -831.72 M SEK profit recorded in the previous year.
The Hansa Biopharma Net Income history
| YEAR | NET INCOME (undefined SEK) |
|---|---|
| 2029e | 1.64 |
| 2028e | 0.1 |
| 2027e | -0.23 |
| 2026e | -0.39 |
| 2025e | -0.58 |
| 2024e | -0.7 |
| 2023 | -0.83 |
| 2022 | -0.61 |
| 2021 | -0.55 |
| 2020 | -0.42 |
| 2019 | -0.36 |
| 2018 | -0.25 |
| 2017 | -0.18 |
| 2016 | -0.11 |
| 2015 | -0.07 |
| 2014 | -0.03 |
| 2013 | -0.02 |
| 2012 | -0.02 |
| 2011 | -0.02 |
| 2010 | -0.02 |
| 2009 | -0.02 |
| 2008 | -0 |
| 2007 | -0 |
Hansa Biopharma Revenue, EBIT, Net Income SE0002148817 · A0M65T
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Hansa Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hansa Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hansa Biopharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Hansa Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Hansa Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Hansa Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hansa Biopharma’s growth potential.
Hansa Biopharma Revenue, Profit, and EBIT History
| Date | Hansa Biopharma Revenue | Hansa Biopharma EBIT | Hansa Biopharma Net Income |
|---|---|---|---|
| 2029e | 4.72 B SEK | 0 SEK | 1.64 B SEK |
| 2028e | 1.73 B SEK | 208.95 M SEK | 104.64 M SEK |
| 2027e | 898.92 M SEK | -249.65 M SEK | -231.68 M SEK |
| 2026e | 583.44 M SEK | -436.03 M SEK | -388.94 M SEK |
| 2025e | 351.86 M SEK | -571.84 M SEK | -575.03 M SEK |
| 2024e | 257.21 M SEK | -600.56 M SEK | -701.16 M SEK |
| 2023 | 134.09 M SEK | -791.16 M SEK | -831.72 M SEK |
| 2022 | 154.53 M SEK | -576.12 M SEK | -611.13 M SEK |
| 2021 | 33.88 M SEK | -539.58 M SEK | -548.28 M SEK |
| 2020 | 6.1 M SEK | -422.81 M SEK | -420.85 M SEK |
| 2019 | 3.36 M SEK | -357.6 M SEK | -360.01 M SEK |
| 2018 | 3.36 M SEK | -246.5 M SEK | -247.97 M SEK |
| 2017 | 3.44 M SEK | -176.08 M SEK | -176.66 M SEK |
| 2016 | 2.58 M SEK | -111.14 M SEK | -111.13 M SEK |
| 2015 | 6.68 M SEK | -66.2 M SEK | -66.27 M SEK |
| 2014 | 4.72 M SEK | -24.71 M SEK | -29.04 M SEK |
| 2013 | 1.73 M SEK | -17.64 M SEK | -17.56 M SEK |
| 2012 | 2.62 M SEK | -16.81 M SEK | -16.47 M SEK |
| 2011 | 1.3 M SEK | -24.46 M SEK | -24.57 M SEK |
| 2010 | 4.45 M SEK | -19.99 M SEK | -18.84 M SEK |
| 2009 | 2.98 M SEK | -15.74 M SEK | -15.81 M SEK |
| 2008 | 100,000 SEK | -15.91 M SEK | -2.56 M SEK |
| 2007 | 0 SEK | -3.64 M SEK | -2.47 M SEK |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2007 | 0 SEK | -3.64 M SEK | -2.47 M SEK |
| 2008 | 100,000 SEK | -15.91 M SEK | -2.56 M SEK |
| 2009 | 2.98 M SEK | -15.74 M SEK | -15.81 M SEK |
| 2010 | 4.45 M SEK | -19.99 M SEK | -18.84 M SEK |
| 2011 | 1.3 M SEK | -24.46 M SEK | -24.57 M SEK |
| 2012 | 2.62 M SEK | -16.81 M SEK | -16.47 M SEK |
| 2013 | 1.73 M SEK | -17.64 M SEK | -17.56 M SEK |
| 2014 | 4.72 M SEK | -24.71 M SEK | -29.04 M SEK |
| 2015 | 6.68 M SEK | -66.2 M SEK | -66.27 M SEK |
| 2016 | 2.58 M SEK | -111.14 M SEK | -111.13 M SEK |
| 2017 | 3.44 M SEK | -176.08 M SEK | -176.66 M SEK |
| 2018 | 3.36 M SEK | -246.5 M SEK | -247.97 M SEK |
| 2019 | 3.36 M SEK | -357.6 M SEK | -360.01 M SEK |
| 2020 | 6.1 M SEK | -422.81 M SEK | -420.85 M SEK |
| 2021 | 33.88 M SEK | -539.58 M SEK | -548.28 M SEK |
| 2022 | 154.53 M SEK | -576.12 M SEK | -611.13 M SEK |
| 2023 | 134.09 M SEK | -791.16 M SEK | -831.72 M SEK |
| 2024e | 257.21 M SEK | -600.56 M SEK | -701.16 M SEK |
| 2025e | 351.86 M SEK | -571.84 M SEK | -575.03 M SEK |
| 2026e | 583.44 M SEK | -436.03 M SEK | -388.94 M SEK |
| 2027e | 898.92 M SEK | -249.65 M SEK | -231.68 M SEK |
| 2028e | 1.73 B SEK | 208.95 M SEK | 104.64 M SEK |
| 2029e | 4.72 B SEK | 0 SEK | 1.64 B SEK |
Hansa Biopharma stock margins SE0002148817 · A0M65T
The Hansa Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hansa Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hansa Biopharma.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Hansa Biopharma's sales revenue. A higher gross margin percentage indicates that the Hansa Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Hansa Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Hansa Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hansa Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hansa Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hansa Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Hansa Biopharma Margin History
| Hansa Biopharma Gross margin | Hansa Biopharma Profit margin | Hansa Biopharma EBIT margin | Hansa Biopharma Profit margin |
|---|---|---|---|
| 2029e | 52.91 % | 0 % | 34.81 % |
| 2028e | 52.91 % | 12.09 % | 6.05 % |
| 2027e | 52.91 % | -27.77 % | -25.77 % |
| 2026e | 52.91 % | -74.74 % | -66.66 % |
| 2025e | 52.91 % | -162.52 % | -163.43 % |
| 2024e | 52.91 % | -233.49 % | -272.6 % |
| 2023 | 52.91 % | -590 % | -620.25 % |
| 2022 | 75.1 % | -372.83 % | -395.49 % |
| 2021 | 54.47 % | -1,592.72 % | -1,618.4 % |
| 2020 | 83.65 % | -6,933.54 % | -6,901.49 % |
| 2019 | 74.26 % | -10,630.05 % | -10,701.81 % |
| 2018 | 72.72 % | -7,340.62 % | -7,384.57 % |
| 2017 | 93.58 % | -5,115.72 % | -5,132.48 % |
| 2016 | 91.59 % | -4,309.23 % | -4,309 % |
| 2015 | 90.14 % | -991.78 % | -992.75 % |
| 2014 | 94.7 % | -523.52 % | -615.25 % |
| 2013 | -569.36 % | -1,019.65 % | -1,015.03 % |
| 2012 | -344.66 % | -641.6 % | -628.63 % |
| 2011 | -1,403.08 % | -1,881.54 % | -1,890 % |
| 2010 | -335.73 % | -449.21 % | -423.37 % |
| 2009 | -346.31 % | -528.19 % | -530.54 % |
| 2008 | -11,350 % | -15,910 % | -2,560 % |
| 2007 | 52.91 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2007 | 52.91 % | 0 % | 0 % |
| 2008 | -11,350 % | -15,910 % | -2,560 % |
| 2009 | -346.31 % | -528.19 % | -530.54 % |
| 2010 | -335.73 % | -449.21 % | -423.37 % |
| 2011 | -1,403.08 % | -1,881.54 % | -1,890 % |
| 2012 | -344.66 % | -641.6 % | -628.63 % |
| 2013 | -569.36 % | -1,019.65 % | -1,015.03 % |
| 2014 | 94.7 % | -523.52 % | -615.25 % |
| 2015 | 90.14 % | -991.78 % | -992.75 % |
| 2016 | 91.59 % | -4,309.23 % | -4,309 % |
| 2017 | 93.58 % | -5,115.72 % | -5,132.48 % |
| 2018 | 72.72 % | -7,340.62 % | -7,384.57 % |
| 2019 | 74.26 % | -10,630.05 % | -10,701.81 % |
| 2020 | 83.65 % | -6,933.54 % | -6,901.49 % |
| 2021 | 54.47 % | -1,592.72 % | -1,618.4 % |
| 2022 | 75.1 % | -372.83 % | -395.49 % |
| 2023 | 52.91 % | -590 % | -620.25 % |
| 2024e | 52.91 % | -233.49 % | -272.6 % |
| 2025e | 52.91 % | -162.52 % | -163.43 % |
| 2026e | 52.91 % | -74.74 % | -66.66 % |
| 2027e | 52.91 % | -27.77 % | -25.77 % |
| 2028e | 52.91 % | 12.09 % | 6.05 % |
| 2029e | 52.91 % | 0 % | 34.81 % |
Hansa Biopharma Aktienanalyse
What does Hansa Biopharma do?
Hansa Biopharma AB is a Swedish biotechnology company specializing in the development of therapy options for rare immune and inflammatory diseases. The company was founded in Lund in 1986 and now has branches in the USA and Japan. The company's business model and divisions include clinical development, corporate development, and production. The clinical development division focuses on conducting clinical studies to demonstrate the effectiveness and safety of new drugs. The corporate development division handles collaboration with regulatory authorities, investors, and other partners. The production division encompasses the manufacturing of products developed by Hansa Biopharma AB. The company's products include Idefirix, an antibody-based drug candidate for the treatment of severe hemolysis due to alloimmune blood group antibodies, and an immunoglobulin production technology platform for the development of antibody therapies for various diseases. Hansa Biopharma AB's roots date back to 1986 when it was established as a spin-off from Lund University. Initially, the company focused on the development and production of diagnostics and reagents for immunology and clinical chemistry. In recent years, it shifted its focus to developing innovative therapies for rare immune and inflammatory diseases. In 2010, the company made a breakthrough with the discovery of the 174H target, which led to the development of Idefirix. Idefirix has since successfully completed phase III clinical trials and may soon be approved for the treatment of severe hemolysis. In conclusion, Hansa Biopharma AB is a leading biotechnology company with a strong vision and clear strategy for developing innovative therapies for rare immune and inflammatory diseases. The company specializes in antibody therapies and is currently focused on the development of Idefirix and the expansion of its immunoglobulin production technology platform. With a strong research pipeline and experienced management team, Hansa Biopharma AB is well-positioned to make significant progress in the coming years and develop innovative therapies for patients with rare diseases. Hansa Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Hansa Biopharma's Profit Margins
The profit margins of Hansa Biopharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Hansa Biopharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Hansa Biopharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Hansa Biopharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Hansa Biopharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Hansa Biopharma Stock
How has the profit developed compared to last year?
The profit has increased by -15.7% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Hansa Biopharma publish its earnings?
Hansa Biopharma publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Hansa Biopharma?
The profits of Hansa Biopharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Hansa Biopharma?
You can learn more about the earnings of Hansa Biopharma by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Hansa Biopharma pay?
Over the past 12 months, Hansa Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hansa Biopharma is expected to pay a dividend of 0 SEK.
What is the dividend yield of Hansa Biopharma?
The current dividend yield of Hansa Biopharma is .
When does Hansa Biopharma pay dividends?
Hansa Biopharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Hansa Biopharma?
Hansa Biopharma paid dividends every year for the past 0 years.
What is the dividend of Hansa Biopharma?
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
In which sector is Hansa Biopharma located?
Hansa Biopharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Hansa Biopharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Hansa Biopharma from 6/19/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.
When did Hansa Biopharma pay the last dividend?
The last dividend was paid out on 6/19/2024.
What was the dividend of Hansa Biopharma in the year 2023?
In the year 2023, Hansa Biopharma distributed 0 SEK as dividends.
In which currency does Hansa Biopharma pay out the dividend?
The dividends of Hansa Biopharma are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Hansa Biopharma
Our stock analysis for Hansa Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hansa Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Hansa Biopharma Revenue
- Hansa Biopharma Net Income
- Hansa Biopharma P/E
- Hansa Biopharma P/S
- Hansa Biopharma EBIT
- Hansa Biopharma Dividend
- Hansa Biopharma Stocks
- Hansa Biopharma Market capitalization
- Hansa Biopharma Debt
- Hansa Biopharma Liabilities
- Hansa Biopharma Equity
- Hansa Biopharma AAQS
- Hansa Biopharma Employees
- Hansa Biopharma ROE
- Hansa Biopharma ROA
- Hansa Biopharma ROCE
